Alector (ALEC) Stock

Alector Inc (NASDAQ: ALEC) is a clinical-stage biopharmaceutical company focused on immuno‑neurology, developing therapies that modulate the immune system to treat neurodegenerative diseases such as Alzheimer’s and ALS. With a market capitalisation of about $324.89M, it sits in the small‑cap, high‑risk segment where valuation is often driven by trial results and regulatory milestones rather than steady revenues. Investors should be aware that Alector’s value is closely tied to the progress of its pipeline, partnering agreements and its ability to raise further capital. Clinical outcomes can be binary and may produce sharp share price moves. Key factors to watch include upcoming data readouts, cash runway, collaboration deals and regulatory interactions. This is general educational information and not personalised investment advice — biotech investing carries significant risk and investors should consider suitability, diversification and time horizon before exposure.